Psoriatic Arthritis
National Psoriasis Foundation to honor leaders at 2025 Commit to Cure Gala
The National Psoriasis Foundation has announced the honorees for this year’s Commit to Cure Gala, according to a press release.
Blue-collar workers more likely to miss work, quit due to psoriatic arthritis
Blue-collar workers with psoriatic arthritis demonstrate an increased risk for work disability vs. white-collar workers with the same disease, according to data published in Clinical Rheumatology.
Healio Minute Podcast, Rheumatology/Psoriatic Arthritis Edition: Top Headlines - Week of August 19, 2024
In this edition, drug discounts through Medicare price negotiations, opioid use has fallen 15% annually since 2014 and more.
‘Pristine’ safety profile sets TYK2i apart from JAK ‘baggage’ in psoriatic disease, lupus
In September 2022, the FDA approved deucravacitinib for moderate-to-severe plaque psoriasis, officially introducing tyrosine kinase 2 inhibition to clinics across the United States.
Enbrel, Stelara to be discounted nearly 70% through Medicare price negotiations
The list prices of Stelara and Enbrel for Medicare users will be discounted nearly 70% come 2026 as a result of the first round CMS price negotiations with drugmakers, the White House has announced.
Inhibitor class PsO treatments exhibit similar efficacy in mitigating PsA risk
Patients treated with interleukin-23i or IL-12/23i for psoriasis exhibited similar rates of risk for developing psoriatic arthritis, according to a study.
EU approves 320 mg Bimzelx, 2 mL devices for multiple inflammatory diseases
The European Commission has granted marketing authorization for two devices that administer Bimzelx for the treatment of multiple inflammatory diseases, UCB announced in a press release.